Novo after crucial data from competitor: Welcomes drug R&D

Investors in both Novo Nordisk and US firm Eli Lilly are highly satisfied with the results from Lilly's grand diabetes hope, tirzepatide. Novo Nordisk already has a potential new superdrug in its pipeline.

Photo: Mike Blake/REUTERS / X00030

Things looked really great, but not to the extent that the firms have hit a home run.

For this reason, Novo Nordisk's and US firm Eli Lilly's investors reacted positively, after Eli Lilly recently presented the first and long-awaited data for drug candidate tirzapetide for the treatment of diabetes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs